Share

RECIST news and updates

Hear Lesley Seymour and Jan Bogaerts  discuss with Helen Saul of EJC News the challenges and possibilities for RECIST

The RECIST Working Group was established in 1995 to review the objective response criteria in use at the time and to explore the utility of the use of unidimensional measurements in response assessment, as proposed by NCIC CTG. The initial working group was led by academic members of the EORTC, NCIC CTG and NCI (USA), with a database being created and maintained under the governance of the EORTC. Over the years, the membership of the Working Group was expanded to include other interested or expert members, including some representation from the pharmaceutical industry, as original members joined pharma, or expertise was identified. RECIST v1 was successfully implemented in 2000, and an update (RECIST 1.1) was released in 2009.

At the TAT Congress held in Paris on 2-4 March 2015, Lesley Seymour (NCIC Clinical Trials Group, Canada and co-chair of the RECIST Working Group) and Jan Bogaerts (Methodology Director EORTC Headquarters in Brussels) respectively chaired and spoke at a ‘Beyond RECIST’ session.

Visit the RECIST Working Group website.

Back to news list

Related News

  • Clinical Trials Day 2024: a Q&A on pragmatic clinical trials

  • EORTC/EMA workshop suggests an international way forward for treatment optimisation studies

  • EORTC’s Participation at the ESTRO Congress 2024

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC